Chengdu Easton Biopharmaceuticals Co., Ltd.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Public
- Established
- 2009-06-01
- Employees
- 1.4K
- Market Cap
- -
- Website
- http://www.eastonpharma.cn
Clinical Trials
2
Active:0
Completed:0
Trial Phases
2 Phases
Phase 1:1
Phase 3:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (50.0%)Phase 3
1 (50.0%)A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Trial to Evaluate the Clinical Efficacy and Safety of Yogliptin Tablets
Phase 3
Recruiting
- Conditions
- Type 2 Diabetes
- Interventions
- Drug: placebo groupDrug: Yogliptin 400mg groupDrug: Yogliptin 200mg group
- First Posted Date
- 2022-04-08
- Last Posted Date
- 2022-04-20
- Lead Sponsor
- Chengdu Easton Biopharmaceuticals Co,Ltd
- Target Recruit Count
- 450
- Registration Number
- NCT05318326
- Locations
- 🇨🇳
Beijing Hospital, Beijing, Beijing, China
a Safety and Tolerability Study of EP-9001A in Healthy Volunteers
- First Posted Date
- 2022-03-14
- Last Posted Date
- 2022-04-04
- Lead Sponsor
- Chengdu Easton Biopharmaceuticals Co,Ltd
- Target Recruit Count
- 44
- Registration Number
- NCT05278611
- Locations
- 🇨🇳
West China Hospital，Sichuan University, Chengdu, Sichuan, China
News
No news found